Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of astragaloside III in preparation of drugs

A technology of astragaloside IV and medicine, which is applied in the field of application of astragaloside IV in the preparation of medicines, and can solve problems such as side effects of healthy cells

Inactive Publication Date: 2018-12-25
LI MIN PHARM FAB OF LIVZON PHARM GRP
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, chemotherapy also has a range of side effects on healthy cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of astragaloside III in preparation of drugs
  • Application of astragaloside III in preparation of drugs
  • Application of astragaloside III in preparation of drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Example 1 Astragaloside III increases the percentage of NK1.1+

[0050] In order to study the effect of astragaloside IV on NK cell products, the inventors activated the lymphocytes of wild-type mice with astragaloside IV for 48 hours, and analyzed the percentage of NK1.1+ cells by flow cytometry. We observed that astragaloside III increased the proportion of NK1.1+ cells in a significant dose-dependent manner.

[0051] Splenocytes from C57 mice were cultured in astragaloside IV concentrate for 48 hours in vitro. At least one-third of independent experiments showed that astragaloside III enhanced NK cell expansion in vitro. The experimental result is figure 1 : Representative flow cytometry NK1.1+ cells scatter plot. figure 2 : is the action curve of astragaloside III on NK1.1+ expression.

Embodiment 2

[0052] Example 2 The effect of astragaloside III on cell division

[0053] Based on the fact that astragaloside III can increase the percentage of NK cells cultured in vitro, the inventors tried to prove whether the compound can produce NK cells in NK gene knockout mice. Wild C57 mice were injected with anti-mouse NK1.1+48 hours to remove NK cells in their bodies. Splenocytes from NK-deficient mice were activated with astragaloside III for 48 hours, and the percentages of NK cells and NKT cells were analyzed by flow cytometry. It was observed that astragaloside IV greatly promoted the proliferation of NK cells. NK cells were enriched and stained with CFSE. NK cells were treated with astragaloside Ⅲ for 48 hours, and then the division of NK cells was analyzed by flow cytometry. We observed that astragaloside III can promote NK cell division.

[0054] Splenocytes from NK cell-deficient mice were activated with 100 nM astragaloside III for 48 hours. Astragaloside IV can pr...

Embodiment 3

[0055] Example 3 The Anticancer Effect of Astragaloside IV

[0056] The treatment of tumors by NK cells varies with tumor cells. In order to confirm the therapeutic effect of astragaloside Ⅲ, its effects on osteosarcoma U20S cells and B16 melanoma cells were compared. Osteosarcoma U20S cells and B16 melanoma cells co-cultured with NK cells were activated with astragaloside IV for 6 hours overnight. Tumor cells were analyzed by MTT. It was observed that the inhibitory effect of astragaloside Ⅲ on B16 melanoma cells was stronger than that on osteosarcoma U20S cells. B16 melanoma cells were stained with CFSE and co-cultured with NK cells, and treated with astragaloside IV for 6 hours overnight. It was observed that astragaloside IV could inhibit the proliferation of B16 melanoma cultured by NK cells.

[0057] In vitro therapeutic effect of astragaloside IV on different cancer cells. NK cell-deficient C57 mice were cultured overnight with astragaloside IV. Different tumor c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of astragaloside III or its pharmaceutically acceptable salts in the preparation of drugs to promote NK cell amplification, and provides application of astragalosideIII or its pharmaceutically acceptable salts in the preparation of drugs to prevent and / or treat cancers, preferably, lung adenocarcinoma or melanoma. The invention provides application of astragaloside III or its pharmaceutically acceptable salts in the preparation of drugs to prevent and / or treat infectious diseases, and application of astragaloside III or its pharmaceutically acceptable saltsin the preparation of drugs to prevent and / or treat immunological diseases. Astragaloside III or its pharmaceutically acceptable salts can effectively promote NK cell amplification compounds, have theadvantages of small potential toxic and side effects, significant inhibition on cancer cell proliferation, broad-spectrum cancer prevention, good preparation convenience, low cost and the like, and have a promising clinical application prospect.

Description

technical field [0001] The present invention relates to the use of an active ingredient of a traditional Chinese medicine in the preparation of a drug for preventing and / or treating diseases and a pharmaceutical composition containing the active ingredient, in particular to the use of astragaloside III or its salt in the preparation of a drug for preventing and treating diseases Use and pharmaceutical composition containing astragaloside III or its salt. Background technique [0002] The traditional therapy of cancer is to induce cytotoxicity to cancer cells through chemotherapy. However, chemotherapy also has a range of side effects on healthy cells. Immunotherapy is thus a rapidly developing field of cancer treatment, showing great potential in recent clinical trials. Immunotherapy treatment involves the following steps: isolation of immune cells from blood, ex vivo cell expansion and introduction of immune cells into the patient. A variety of immune cells can be induce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P31/00A61P35/00A61P37/04A61P37/02
CPCA61K31/7048
Inventor 黄文华陈曦刘亮锋李正汪冰冰江晓漫
Owner LI MIN PHARM FAB OF LIVZON PHARM GRP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com